Esko E, Renkonen O V
Scand J Infect Dis. 1985;17(1):95-8. doi: 10.3109/00365548509070427.
The in vitro activity of norfloxacin, a new quinolone derivative, was tested against 469 clinical isolates derived mainly from urinary samples from outpatients. It inhibited all Escherichia coli, Klebsiella oxytoca and Proteus strains at a concentration of 0.25 micrograms/ml, and all Pseudomonas aeruginosa, Enterobacter, Klebsiella pneumoniae, Staphylococcus and Enterococcus strains at a concentration of 8 micrograms/ml or less. Norfloxacin proved to be more effective than nalidixic acid, trimethoprim, mecillinam and nitrofurantoin against all gram-negative rods tested.
对一种新的喹诺酮衍生物诺氟沙星的体外活性进行了测试，受试对象为469株主要来自门诊患者尿液样本的临床分离菌。它在浓度为0.25微克/毫升时可抑制所有大肠杆菌、产酸克雷伯菌和变形杆菌菌株，在浓度为8微克/毫升或更低时可抑制所有铜绿假单胞菌、肠杆菌、肺炎克雷伯菌、葡萄球菌和肠球菌菌株。结果证明，诺氟沙星对所有测试的革兰氏阴性杆菌的抗菌效果均优于萘啶酸、甲氧苄啶、美西林和呋喃妥因。
